Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease

Marla C. Dubinsky, Joel Rosh, William Alvis Faubion, Jaroslaw Kierkus, Frank Ruemmele, Jeffrey S. Hyams, Samantha Eichner, Yao Li, Bidan Huang, Nael M. Mostafa, Andreas Lazar, Roopal B. Thakkar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: The efficacy of adalimumab in inducing and maintaining remission in children with moderately to severely active Crohn's disease was shown in the IMAgINE 1 trial (NCT00409682). As per protocol, nonresponders or patients experiencing flare(s) on every other week (EOW) maintenance dosing could escalate to weekly dosing; we aimed to determine the therapeutic benefits of weekly dose escalation in this subpopulation. Methods: Week 52 remission and response rates were assessed in patients who escalated to weekly dosing from their previous EOW schedule, which was according to randomized treatment dose (higher dose [HD] adalimumab [≥40 kg, 40 mg EOW;

Original languageEnglish (US)
Pages (from-to)886-893
Number of pages8
JournalInflammatory Bowel Diseases
Volume22
Issue number4
DOIs
StatePublished - Mar 9 2016

Fingerprint

Crohn Disease
Pediatrics
Safety
Appointments and Schedules
Maintenance
Therapeutics
Adalimumab

Keywords

  • adalimumab
  • disease flare
  • dose adjustment
  • dose escalation
  • pediatric Crohn's disease

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease. / Dubinsky, Marla C.; Rosh, Joel; Faubion, William Alvis; Kierkus, Jaroslaw; Ruemmele, Frank; Hyams, Jeffrey S.; Eichner, Samantha; Li, Yao; Huang, Bidan; Mostafa, Nael M.; Lazar, Andreas; Thakkar, Roopal B.

In: Inflammatory Bowel Diseases, Vol. 22, No. 4, 09.03.2016, p. 886-893.

Research output: Contribution to journalArticle

Dubinsky, MC, Rosh, J, Faubion, WA, Kierkus, J, Ruemmele, F, Hyams, JS, Eichner, S, Li, Y, Huang, B, Mostafa, NM, Lazar, A & Thakkar, RB 2016, 'Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease', Inflammatory Bowel Diseases, vol. 22, no. 4, pp. 886-893. https://doi.org/10.1097/MIB.0000000000000715
Dubinsky, Marla C. ; Rosh, Joel ; Faubion, William Alvis ; Kierkus, Jaroslaw ; Ruemmele, Frank ; Hyams, Jeffrey S. ; Eichner, Samantha ; Li, Yao ; Huang, Bidan ; Mostafa, Nael M. ; Lazar, Andreas ; Thakkar, Roopal B. / Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease. In: Inflammatory Bowel Diseases. 2016 ; Vol. 22, No. 4. pp. 886-893.
@article{266fd20c8ba742249e422c7c7e9bb97e,
title = "Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease",
abstract = "Background: The efficacy of adalimumab in inducing and maintaining remission in children with moderately to severely active Crohn's disease was shown in the IMAgINE 1 trial (NCT00409682). As per protocol, nonresponders or patients experiencing flare(s) on every other week (EOW) maintenance dosing could escalate to weekly dosing; we aimed to determine the therapeutic benefits of weekly dose escalation in this subpopulation. Methods: Week 52 remission and response rates were assessed in patients who escalated to weekly dosing from their previous EOW schedule, which was according to randomized treatment dose (higher dose [HD] adalimumab [≥40 kg, 40 mg EOW;",
keywords = "adalimumab, disease flare, dose adjustment, dose escalation, pediatric Crohn's disease",
author = "Dubinsky, {Marla C.} and Joel Rosh and Faubion, {William Alvis} and Jaroslaw Kierkus and Frank Ruemmele and Hyams, {Jeffrey S.} and Samantha Eichner and Yao Li and Bidan Huang and Mostafa, {Nael M.} and Andreas Lazar and Thakkar, {Roopal B.}",
year = "2016",
month = "3",
day = "9",
doi = "10.1097/MIB.0000000000000715",
language = "English (US)",
volume = "22",
pages = "886--893",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease

AU - Dubinsky, Marla C.

AU - Rosh, Joel

AU - Faubion, William Alvis

AU - Kierkus, Jaroslaw

AU - Ruemmele, Frank

AU - Hyams, Jeffrey S.

AU - Eichner, Samantha

AU - Li, Yao

AU - Huang, Bidan

AU - Mostafa, Nael M.

AU - Lazar, Andreas

AU - Thakkar, Roopal B.

PY - 2016/3/9

Y1 - 2016/3/9

N2 - Background: The efficacy of adalimumab in inducing and maintaining remission in children with moderately to severely active Crohn's disease was shown in the IMAgINE 1 trial (NCT00409682). As per protocol, nonresponders or patients experiencing flare(s) on every other week (EOW) maintenance dosing could escalate to weekly dosing; we aimed to determine the therapeutic benefits of weekly dose escalation in this subpopulation. Methods: Week 52 remission and response rates were assessed in patients who escalated to weekly dosing from their previous EOW schedule, which was according to randomized treatment dose (higher dose [HD] adalimumab [≥40 kg, 40 mg EOW;

AB - Background: The efficacy of adalimumab in inducing and maintaining remission in children with moderately to severely active Crohn's disease was shown in the IMAgINE 1 trial (NCT00409682). As per protocol, nonresponders or patients experiencing flare(s) on every other week (EOW) maintenance dosing could escalate to weekly dosing; we aimed to determine the therapeutic benefits of weekly dose escalation in this subpopulation. Methods: Week 52 remission and response rates were assessed in patients who escalated to weekly dosing from their previous EOW schedule, which was according to randomized treatment dose (higher dose [HD] adalimumab [≥40 kg, 40 mg EOW;

KW - adalimumab

KW - disease flare

KW - dose adjustment

KW - dose escalation

KW - pediatric Crohn's disease

UR - http://www.scopus.com/inward/record.url?scp=84962235884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962235884&partnerID=8YFLogxK

U2 - 10.1097/MIB.0000000000000715

DO - 10.1097/MIB.0000000000000715

M3 - Article

C2 - 26950307

AN - SCOPUS:84962235884

VL - 22

SP - 886

EP - 893

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 4

ER -